Synthesis and potent antiprotozoal activity of mono/di amidino 2-anilinobenzimidazoles versus Plasmodium falciparum and Trypanosoma brucei rhodesiense.

Çiğdem Karaaslan,M. Kaiser,R. Brun,H. Göker

DOI: https://doi.org/10.1016/j.bmc.2016.06.047

IF: 3.461

2016-09-15

Bioorganic & Medicinal Chemistry

Abstract:

What problem does this paper attempt to address?

Transurethral En Bloc Resection Versus Standard Resection of Bladder Tumour: A Randomised, Multicentre, Phase 3 Trial

Jeremy Yuen-Chun Teoh,Cheung-Hing Cheng,Chiu-Fung Tsang,Joseph Kai-Man Li,Bryan Kwun-Chung Cheng,Wilson Hoi-Chak Chan,Wayne Kwun-Wai Chan,Trevor Churk-Fai Li,Yi Chiu,Man-Chung Law,Clarence Lok-Hei Leung,Brian Sze-Ho Ho,Chris Yue-Kit Lee,Ronald Cheong-Kin Chan,Eddie Shu-Yin Chan,Marco Tsz-Yeung Chan,James Hok-Leung Tsu,Ho-Man Tam,Kin-Man Lam,Hing-Shing So,Chak-Lam Cho,Chi-Man Ng,Chun-Ki Chan,Pak-Ling Liu,Ringo Wing-Hong Chu,Ada Tsui-Lin Ng,Sau-Kwan Chu,Chi-Hang Yee,Ming-Kwong Yiu,Ka-Lun Lo,Wing-Hang Au,Wai-Kit Ma,Peter Ka-Fung Chiu,Hilda Sze-Wan Kwok,Siu-Ying Yip,Chi-Ho Leung,Chi-Fai Ng,EB-StaR Study Group

DOI: https://doi.org/10.1016/j.eururo.2024.04.015

Abstract:Background and objective: Conventionally, standard resection (SR) is performed by resecting the bladder tumour in a piecemeal manner. En bloc resection of the bladder tumour (ERBT) has been proposed as an alternative technique in treating non-muscle-invasive bladder cancer (NMIBC). The objective of this study is to investigate whether ERBT could improve the 1-yr recurrence rate of NMIBC, as compared with SR. Methods: A multicentre, randomised, phase 3 trial was conducted in Hong Kong. Adults with bladder tumour(s) of ≤ 3cm were enrolled from April 2017 to December 2020, and followed up until 1 yr after surgery. Patients were randomly assigned to receive either ERBT or SR in a 1:1 ratio. The primary outcome was 1-yr recurrence rate. A modified intention-to-treat analysis on patients with histologically confirmed NMIBC was performed. The main secondary outcomes included detrusor muscle sampling rate, operative time, hospital stay, 30-d complications, any residual or upstaging of disease upon second-look transurethral resection, and 1-yr progression rate. Key findings and limitations: A total of 350 patients underwent randomisation, and 276 patients were histologically confirmed to have NMIBC. At 1 yr, 31 patients in the ERBT group and 46 in the SR group developed recurrence; the Kaplan-Meier estimate of 1- yr recurrence rates were 29% (95% confidence interval, 18-37) in the ERBT group and 38% (95% confidence interval, 28-46) in the SR group (p = 0.007). Upon a subgroup analysis, patients with 1-3 cm tumour, single tumour, Ta disease, or intermediate-risk NMIBC had a significant benefit from ERBT. None of the patients in the ERBT group and three patients in the SR group developed progression to muscle-invasive bladder cancer; the Kaplan-Meier estimates of 1-yr progression rates were 0% in the ERBT group and 2.6% (95% confidence interval, 0-5.5) in the SR group (p = 0.065). The median operative time was 28 min (interquartile range, 20-45) in the ERBT group and 22 min (interquartile range, 15-30) in the SR group (p < 0.001). All other secondary outcomes were similar in the two groups. Conclusions and clinical implications: In patients with NMIBC of ≤ 3cm, ERBT resulted in a significant reduction in the 1-yr recurrence rate when compared with SR. The study results support ERBT as the first-line surgical treatment for patients with bladder tumours of≤ 3cm.
An international multicentre randomised controlled trial of en bloc resection of bladder tumour vs conventional transurethral resection of bladder tumour: first results of the en bloc resection of urothelium carcinoma of the bladder (EBRUC) II trial

Julian Peter Struck,Nadim Moharam,Armin Leitenberger,Jörg Weber,Lukas Lusuardi,David Oswald,Jens J. Rassweiler,Marcel Fiedler,Jakub Horňák,Marek Babjuk,Salvatore Micali,Carlo Zaraca,Thomas Spreu,Frank Friedersdorff,Hendrik Borgmann,Axel S. Merseburger,Mario W. Kramer

DOI: https://doi.org/10.1111/bju.16543

2024-10-29

BJU International

Abstract:Objectives To determine the safety and oncological advantages of en bloc resection of bladder tumour (ERBT) vs conventional transurethral resection of bladder tumour (cTURBT) in terms of resection quality, staging quality, and safety. Patients and Methods We conducted a single‐blinded randomised controlled trial at seven European hospitals with the following inclusion criteria: first diagnosis of non‐muscle‐invasive bladder cancer, no singular carcinoma in situ, and tumour size >4.3 mm. Patients were randomised intraoperatively in a 1:1 ratio to either the ERBT or cTURBT group. Outcome analysis was performed using the chi‐square test, t‐test, and multivariate regression analysis. Results A total of 97 patients were randomised into the study (cTURBT = 40, ERBT = 57). A switch to cTURBT was necessary in two patients (3.5%) and 11.5% of the screened patients were preoperatively excluded for ERBT. There was no difference in the specimen presence of detrusor muscle with 73.7% in cTURBT and 67.3% in ERBT specimens (P = 0.69). There were no significant differences in mean operative time (ERBT 27.6 vs cTURBT 25.4 min, P = 0.450) or mean resection time (ERBT 16.3 vs cTURBT 15.5 min, P = 0.732). Overall the complication rate did not differ significantly (ERBT 18.2% vs cTURBT 7.5%, P = 0.142). Bladder perforations occurred significantly more often in the ERBT group (ERBT seven vs cTURBT none, P = 0.020). R0 status was reported more often after ERBT, whilst a second resection was significantly less frequent after ERBT (P = 0.018). Recurrence rates were comparable for both techniques after 6 months of follow‐up. Conclusion The feasibility of ERBT is higher than previously reported. Whereas other perioperative and safety parameters are comparable to cTURBT, bladder perforations occurred significantly more often in the ERBT group and raised safety concerns. This is why this trial was terminated.

urology & nephrology
Nonprescription Ibuprofen: Side Effect Profile

S. Furey,J. Waksman,Barry H. Dash

DOI: https://doi.org/10.1002/j.1875-9114.1992.tb04479.x

1992-09-10

Pharmacotherapy

Abstract:Single doses of nonprescription analgesics are commonly used to treat self‐diagnosed conditions. To evaluate the safety of single doses of nonprescriptionstrength ibuprofen, we examined reported side effects from 15 double‐blind, randomized, controlled trials we conducted of the drug to treat various common painful conditions (e.g., headache, sore throat). All studies included placebo and another nonprescription analgesic, acetaminophen. A total of 878 subjects received ibuprofen 200 or 400 mg, 849 acetaminophen 650 or 1000 mg, and 852 placebo. The overall frequency of side effects was comparable: ibuprofen 2.4%, acetaminophen 3.2%, and placebo 2.1%. The frequency of central nervous system symptoms was 0.8%, 2.1%, and 0.9%, respectively. Upper gastrointestinal upset ranged from 0.8–0.9% of subjects in all groups. We conclude that single doses of nonprescription ibuprofen are well tolerated and demonstrate a side effect profile indistinguishable from that of acetaminophen and placebo.
Efficiency of transurethral en‐bloc resection vs. conventional transurethral resection for non‐muscle‐invasive bladder cancer: An umbrella review

Deng‐xiong Li,Qing‐xin Yu,Rui‐cheng Wu,Jie Wang,De‐chao Feng,Shi Deng

DOI: https://doi.org/10.1002/cam4.7323

IF: 4.711

2024-06-01

Cancer Medicine

Abstract:Background En‐Bloc transurethral resection of bladder tumor (ERBT) was clinically used to resect non‐muscle‐invasive bladder cancer (NMIBC). However, discrepancies persist regarding the comparisons between ERBT and conventional transurethral resection of bladder tumor (cTURBT). Methods We conducted a comprehensive search in PubMed, Embase, Web of Science, Cochrane Database of Systematic Reviews, and performed manual searches of reference lists to collect and extract data. Data evaluation was carried out using Review Manager 5.4.0, Rx64 4.1.3, and relevant packages. Results There were nine eligible meta‐analyses and nine eligible RCTs in our study. NMIBC patients undergoing ERBT were significant associated with a lower rate of bladder perforation and obturator nerve reflex compared to those receiving cTURBT. Our pooled result indicated that ERBT and cTURBT required similar operation time. Regarding postoperative outcomes, ERBT demonstrated superior performance compared to cTURBT in terms of detrusor muscle presence, catheterization time, and residual tumor. ERBT exhibited a higher rate of three‐month recurrence‐free survival (RFS) compared to those receiving cTURBT (p

oncology
Sollten wir alle zur En Bloc Resektion von Blasentumoren wechseln?

Jonas Herrmann,Friedrich Otto Hartung,Maximilian C. Kriegmair,Benedikt Becker,Lukas Lusuardi,Thomas R. W. Herrmann,Christopher Netsch

DOI: https://doi.org/10.1055/a-2252-0237

2024-04-25

Aktuelle Urologie

Abstract:Bei der En-Bloc-Resektion von Blasentumoren (ERBT) erfolgt die Abtragung von Tumoren nicht fragmentiert, sondern sie werden in einer Schicht präpariert und, wenn möglich, in toto extrahiert. Diese Methode repräsentiert einen Paradigmenwechsel in der Behandlung nicht muskelinvasiver Blasentumore und bietet gegenüber der konventionellen transurethralen Resektion der Blase (TUR-B) diverse Vorteile. Insbesondere erlauben die so gewonnen histologischen Präparate eine genauere Aufarbeitung, was eine präzisere Stadieneinteilung ermöglicht. Zudem wird häufiger Detrusormuskulatur im Präparat nachgewiesen, was auf eine komplettere Tumorentfernung hindeutet. In den letzten Jahren festigt sich eine stabile Datenbasis, die die Vorteile dieser Technik bekräftigt. So wurde kürzlich in einer multizentrischen, prospektiv-randomisierten Studie erstmals ein signifikanter Vorteil hinsichtlich der Rezidivrate nach 12 Monaten im Vergleich zur TUR-B nachgewiesen. Versierte Endourologen sollten sich mit dieser Technik befassen, da sie sich mittelfristig zum Standard entwickeln könnte. Die Technik ist zu gut und zu elegant, um ignoriert zu werden. In En-Bloc Resection of Bladder Tumours (ERBT), tumours are not removed in fragments, but are dissected in one layer and, if possible, extracted in one piece. This method represents a significant shift in the surgical management of non-muscle-invasive bladder tumours, providing multiple benefits over the traditional transurethral resection of the bladder (TUR-B). The histological analysis of ERBT specimens is more accurate, enhancing diagnostic precision. Additionally, the presence of detrusor muscle in ERBT specimens is more frequent, indicating a more complete removal of the tumours. Recent years have seen the consolidation of a robust evidence base emphasizing the advantages of ERBT. Notably, a multicentric, prospective randomized trial has recently revealed a significant reduction in recurrence rates at 12 months follow-up compared with TUR-B. Experienced endourologists should explore this technique, as it may soon become the standard of care. The technique's elegance and effectiveness make it too important to be ignored. Received: 29 January 2024 Accepted after revision: 04 March 2024 Article published online: 23 April 2024 © 2024. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

urology & nephrology
Comparison of the efficacy and feasibility of en bloc transurethral resection of bladder tumor versus conventional transurethral resection of bladder tumor: A meta-analysis.

Yu-Peng Wu,Ting-Ting Lin,Shao-Hao Chen,Ning Xu,Yong Wei,Jin-Bei Huang,Xiong-Lin Sun,Qing-Shui Zheng,Xue-Yi Xue,Xiao-Dong Li

DOI: https://doi.org/10.1097/MD.0000000000005372

IF: 1.6

2016-01-01

Medicine

Abstract:Background: The aim of this meta-analysis was to compare the feasibility of en bloc transurethral resection of bladder tumor (ETURBT) versus conventional transurethral resection of bladder tumor (CTURBT). Methods: Relevant trials were identified in a literature search of MEDLINE, EMBASE, Cochrane Library, Web of Science, and Google Scholar using appropriate search terms. All comparative studies reporting participant demographics, tumor characteristics, study characteristics, and outcome data were included. Results: Seven trials with 886 participants were included, 438 underwent ETURBT and 448 underwent CTURBT. There was no significant difference in operation time between 2 groups (P=0.38). The hospitalization time (HT) and catheterization time (CT) were shorter in ETURBT group (mean difference[MD] -1.22, 95% confidence interval [CI] -1.63 to -0.80, P<0.01; MD -0.61, 95% CI -1.11 to -0.11, P<0.01). There was significant difference in 24-month recurrence rate (24-month RR) (odds ratio [OR] 0.66, 95% CI 0.47-0.92, P=0.02). The rate of complication with respect to bladder perforation (P=0.004), bladder irritation (P<0.01), and obturator nerve reflex (P<0.01) was lower in ETURBT. The postoperative adjuvant intravesical chemotherapy was evaluated by subgroup analysis, and 24-month RR in CTURBT is higher than that in ETURBT in mitomycin intravesical irrigation group (P=0.02). Conclusion: The first meta-analysis indicates that ETURBT might prove to be preferable alternative to CTURBT management of nonmuscle invasive bladder carcinoma. ETURBT is associated with shorter HT and CT, less complication rate, and lower recurrence-free rate. Moreover, it can provide high-qualified specimen for the pathologic diagnosis. Well designed randomized controlled trials are needed to make results comparable.
Using of en-bloc resection of the bladder wall with a tumor in the treatment of non-muscle invasive bladder cancer.

S. V. Kotov,R. I. Guspanov,A. L. Khachatryan,S. A. Pulbere,Sh. M. Sargsyan,A. K. Zhuravleva

DOI: https://doi.org/10.17650/1726-9776-2022-18-4-120-128

2023-02-28

Cancer Urology

Abstract:Background. Bladder cancer is in the top ten most common onco-urological diseases. Its most common form – non-muscle invasive bladder cancer – is one of the most expensive for healthcare and requires many resources for diagnosis and treatment. Aim. To evaluate safety and effectiveness of en bloc transurethral resection (eTUBRT) of bladder wall with tumor compared to conventional transurethral resection (cTUBRT) in context of recurrence-free survival and perspectives of widespread implementation in onco-urological practice. Materials and methods. We have performed a search and analysis of Russian and international literature in the PubMed database on “en-bloc resection of bladder cancer” regarding information about recurrence-free survival in patients after eTURBT and cTURBT, intraand perioperative complications, overall survival, disease progression, and different surgical techniques. References in the sources were also analyzed to identify additional potentially relevant studies. Results. The analysis of the data showed that eTURBT is safer in regards to intraand postoperative complications, and it has better long-term oncological outcomes and quality of extracted histological material. Additionally, no significant differences in treatment outcomes with different instruments (monopolar, bipolar electric current, different laser equipment) were discovered. Conclusion. eTURBT has several advantages compared to cTURBT in treatment of non-muscle invasive bladder cancer and is a potential alternative to cTURBT. However, further research is required to evaluate the place and capabilities of eTURBT in the arsenal of an onco-urologist.
Minilaparoscopy-Assisted En Bloc Transurethral Resection Of Bladder Tumors

Yunzhi Lin,Ning Xu,Yupeng Wu,Xiaodong Li,Qingshui Zheng,Xueyi Xue,Yong Wei

2018-01-01

Abstract:Objective: To investigate the feasibility and efficacy of the application of minilaparoscopy-assisted en bloc transurethral resection of bladder tumors (TURBT). Methods: A total of 63 patients who underwent minilaparoscopy-assisted en bloc TURBT were evaluated. A plasmakinetic resection system was used during the operations. The minilaparoscopy instruments were placed in the bladder cavity from the puncture point, which was located at the ventral suprapubic midline. After the minilaparoscopy instruments had been placed in the bladder cavity, the bladder tumor was clamped and lifted, and then the tumor was dissected through the superficial muscular layer under the circumferentially incised area. Results: Among all 63 patients, the mean operation time and hospitalization time were 39.8 +/- 23.7 minutes and 4.7 +/- 1.7 days, respectively, and the mean catheterization time and bladder irrigation times were 3.4 +/- 1.7 days and 1 day, respectively. Intraoperative hemorrhage was rare, and no obturator nerve reflex occurred. The pathological staging and depth of invasion were accurately evaluated in all specimens. Conclusion: This study demonstrated that minilaparoscopy-assisted en bloc TURBT is a safe and effective procedure that provides an alternative treatment for bladder tumor with minor trauma, few complications, and quick recovery. The pathological stage, depth of invasion, and positive margin status were accurately evaluated in all high-quality specimens.
ERAS for Ambulatory TURBT: Enhancing Bladder Cancer Care (EMBRACE) randomised controlled trial protocol

Rezaee,M. E.,Mahon,K. M.,Trock,B. J.,Nguyen,T.-H. E.,Smith,A. K.,Hahn,N. M.,Patel,S. H.,Kates,M.

DOI: https://doi.org/10.1136/bmjopen-2023-076763

IF: 3.006

2024-06-12

BMJ Open

Abstract:Introduction Transurethral resection of bladder tumour (TURBT) is one of the more common procedures performed by urologists. It is often described as an 'incision-free' and 'well-tolerated' operation. However, many patients experience distress and discomfort with the procedure. Substantial opportunity exists to improve the TURBT experience. An enhanced recovery after surgery (ERAS) protocol designed by patients with bladder cancer and their providers has been developed. Methods and analysis This is a single-centre, randomised controlled trial to investigate the effectiveness of an ERAS protocol compared with usual care in patients with bladder cancer undergoing ambulatory TURBT. The ERAS protocol is composed of preoperative, intraoperative and postoperative components designed to optimise each phase of perioperative care. 100 patients with suspected or known bladder cancer aged ≥18 years undergoing initial or repeat ambulatory TURBT will be enrolled. The change in Quality of Recovery 15 score, a measure of the quality of recovery, between the day of surgery and postoperative day 1 will be compared between the ERAS and control groups. Ethics and dissemination The trial has been approved by the Johns Hopkins Institutional Review Board #00392063. Participants will provide informed consent to participate before taking part in the study. Results will be reported in a separate publication. Trial registration number NCT05905276

medicine, general & internal
Prognostic value of micrometric substaging in pT1 bladder cancer patients treated with en‐bloc transurethral resection

Takafumi Yanagisawa,Shun Sato,Yasushi Hayashida,Yohei Okada,Akihiro Matsukawa,Kosuke Iwatani,Masayuki Shimoda,Hiroyuki Takahashi,Takahiro Kimura,Shahrokh F Shariat,Jun Miki

DOI: https://doi.org/10.1111/his.15177

2024-03-15

Histopathology

Abstract:Aims We aimed to assess the oncological impact of micrometric extent of invasion in patients with pT1 bladder cancer (BCa) who underwent en‐bloc resection for bladder tumour (ERBT). Methods and results We retrospectively analysed the records and specimens of 106 pT1 high‐grade BCa patients who underwent ERBT. The extent of invasion, such as depth from basal membrane, number of invasive foci, maximum width of invasive focus, muscularis mucosae invasion and infiltration pattern (pattern A: solid sheet‐like, nodular or nested growth, pattern B: trabecular, small cluster or single‐cell pattern) were evaluated by a single genitourinary pathologist. The end‐points were recurrence‐free (RFS) and progression‐free survival (PFS). Within a median follow‐up of 23 months, overall, 36 patients experienced recurrence and 13 patients experienced disease progression. The 2‐year PFS differed significantly depending on depth from basal membrane (

pathology,cell biology
Thulium laser en bloc resection reduces recurrence rates in NMIBC patients with tumor diameters ≥3cm compared to transurethral resection: a non-randomized controlled study

Zhipeng Yao,Yang Li,Yuhong Ding,Yaxin Hou,Junyi Hu,Zhenghao Liu,Pengjie Shi,Henglong Hu,Fan Li,Jia Hu,Wen Song,Xiaodong Song,Ke Chen,Lilong Liu,Zheng Liu

DOI: https://doi.org/10.1186/s12885-024-13022-x

IF: 4.638

2024-10-10

BMC Cancer

Abstract:The advantages of en bloc resection of bladder tumors (ERBT) over transurethral resection of bladder tumors (TURBT) in terms of patient prognosis are not yet clear, and there are some technical limitations. We aimed to compare the tumor recurrence in non-muscle invasive bladder cancer (NMIBC) patients with tumor diameter ≥ 3 cm undergoing either TURBT or thulium laser ERBT.

oncology
On the Terminology of VVT

T. Hoppe,P. Meseguer

Abstract:
Organ-Sparing Strategies in Muscle-Invasive Bladder Cancer

J Alfred Witjes,Astrid A H Feikema

DOI: https://doi.org/10.2147/CMAR.S294099

2021-10-13

Abstract:Radical cystectomy (RC) is the treatment of choice and is strongly recommended for patients with pT2-4aN0M0 bladder cancer in both the European Association of Urology (EAU) and American Urological Association (AUA) muscle-invasive bladder cancer (MIBC) guidelines. RC is a challenging operation, with significant perioperative and postoperative morbidity and mortality, having short-term complication rates between 14.4% and 21.7%, and long-term oncological survival rates ranging from 60% after 5 years to 43% after 10 years. The impact on quality of life (QoL) in patients after treatment for bladder cancer is significantly worse than in other pelvic cancers. Although RC is strongly recommended as the gold standard, there is a need for bladder-sparing options in MIBC. Attempts to improve mortality and morbidity rates after RC have been made by implementing Enhanced Recovery After Surgery (ERAS), robot-assisted RC, and sexual function-preserving techniques. None of these significantly improves QoL or functional outcome. Because of the invasiveness of RC, other therapeutic options have been evaluated. Transurethral resection of the bladder tumor (TURB) plays an important role in the diagnostic evaluation of MIBC and has also been reviewed as a curative option, although the oncological results appear inferior to RC. Furthermore, improved radiotherapy (RT) and widely used chemotherapy, both as monotherapeutic options in bladder cancer, are not as effective as radical surgery, with lower survival rates. Trimodality treatment (TMT) in bladder cancer combines TURB with chemotherapy and RT. The goal of TMT is preserving the bladder and QoL without compromising oncological outcome. A 2018 review showed no difference in overall survival rates between RC and TMT (30.9% vs 35.1%), with lower survival rates after RC than TMT in the first year of follow-up, probably due to higher postoperative mortality. For a selected group of patients, TMT is to be recommended, and it is the most favorable option out of the organ-sparing strategies in MIBC.
High-power green-light laser endoscopic submucosal dissection for non-muscle-invasive bladder cancer: A technical improvement and its initial application

Jilu Zheng,Feifan Liu,Keqin Zhang,Yuzhu Xiang,Lianjun Li,Haiyang Zhang,Yinan Zhang,Ning Suo,Zilong Wang,Chenglin Han,Xunbo Jin,Muwen Wang,Chunxiao Wei,Ji Chen

DOI: https://doi.org/10.4103/jcrt.jcrt_674_22

Abstract:Background: The technique of laser en bloc resection of bladder tumor (ERBT) has been a valuable alternative technique to transurethral resection of bladder tumor (TURBT). However, the combination of laser ERBT and endoscopic submucosal dissection (ESD) technique has not been well studied. Here, a novel technique integrating a high-power green-light laser with ESD was presented. This study aimed to evaluate the safety and efficacy of high-power green-light laser endoscopic submucosal dissection (HPL-ESD) for the treatment of primary non-muscle-invasive bladder cancer (NMIBC). Materials and methods: From January 2015 to December 2018, a total of 56 patients with NMIBC underwent HPL-ESD. All tumors were transurethral en bloc resected in the ESD technique. Perioperative clinical data were retrospectively collected and analyzed. Results: All operations were safely performed by the technique of HPL-ESD without blood transfusion. The mean tumor diameter was 2.04 ± 0.65 cm, ranging from 0.5 to 3.5 cm. The mean operative time was 28.39 ± 16.04 min. The average serum hemoglobin decrease was 0.88 ± 0.54 g/dL. The mean postoperative catheterization time was 2.88 ± 0.94 days. The pathologic stages included pTa (32 cases), and pT1 (24 cases). Double-J stent indwelling was not performed for four patients whose tumors were adjacent to the ureteral orifice and no postoperative hydronephrosis was observed. Only one case of ectopic bladder tumor recurred due to irregular bladder irrigation during the 36-month follow-up. Conclusion: HPL-ESD is a safe and effective alternative for the treatment of primary NMIBCs, especially for tumors adjacent to the ureteral orifice.
Transurethral plasma kinetic resection of superficial bladder tumor

XU Qing-quan,HUANG Xiao-bo,HE Cong-jun

2008-01-01

Abstract:Objective To evaluate the efficacy and safety of transurethral plasma kinetic resection of bladder tumor(PKRBt).Methods The data of 30 cases undergoing PKRBt procedures between April 2005 and June 2007 were reviewed retrospectively.There were 26 males and 4 females,aged between 36 and 93 years with on average of 65 years.Eleven tumors were located at the left wall,13 at the right wall,other 6 at triangle region and other sites.Tumor size was 0.5-3.1 cm.Results All tumors were successfully removed by transurethral PKRBt procedures.Operation time was 15-75 minutes,with an average of 40 minutes.No patient needed transfusion.Bladder perforation occurred and was cured by catheterization in 2 cases.The internal obturator muscle reflex was found in three cases.All patients were followed up for 3-26 months.Tumor recurrence was found in 6 patients,of whom,5 received PKRBt procedures again and the other one received radical cystectomy.Conclusion Transurethral PKRBt is effective and safe in treating superficial bladder tumors and should be done cautiously in resecting side wall tumors and small piece of tissue.
Reducing recurrence in non-muscle-invasive bladder cancer by systematically implementing guideline-based recommendations: effect of a prospective intervention in primary bladder cancer patients

Anne Sörenby,Gediminas Baseckas,Pär-Ola Bendahl,Johan Brändstedt,Ulf Håkansson,Stefan Nilsson,Oliver Patschan,Martina Tinzl,Mats Wokander,Fredrik Liedberg,Sigurdur Gudjonsson

DOI: https://doi.org/10.1080/21681805.2019.1604568

Abstract:Objective: In non-muscle-invasive bladder cancer (NMIBC), local recurrence after transurethral resection of the bladder (TURB) is common. Outcomes vary between urological centres, partly due to the sub-optimal surgical technique and insufficient application of measures recommended in the guidelines. This study evaluated early recurrence rates after primary TURB for NMIBC before and after introducing a standardized treatment protocol. Methods: Medical records of all patients undergoing primary TURB for NMIBC in 2010 at Skåne University Hospital, Malmö, Sweden, were reviewed. A new treatment protocol for NMIBC was defined and introduced in 2013, and results documented during the first year thereafter were compared with those recorded in 2010 prior to the intervention. The primary endpoint was early recurrence at first control cystoscopy. Comparisons were made by Chi-square analysis and Fisher's exact test. Recurrence-free survival (RFS) in the two cohorts was also investigated. Results: TURB was performed on 116 and 159 patients before and after the intervention, respectively. The early recurrence rate decreased from 22% to 9.6% (p = 0.005) at the first control cystoscopy after treatment. Residual/Recurrent tumour at the first control cystoscopy after the primary TURB (i.e. at second-look resection or first control cystoscopy) decreased from 31% to 20% (p = 0.038). The proportion of specimens containing muscle in T1 tumours increased from 55% to 94% (p < 0.001). RFS was improved in the intervention group (HR = 0.65, CI = 0.43-1.0; p = 0.05). Conclusions: Introduction of a standardized protocol and reducing the number of surgeons for primary treatment of NMIBC decreased the early recurrence rate from 22% to 9.6% and lowered the recurrence incidence by 35%.
Predicting residual rectal adenocarcinoma in the surgical specimen after preoperative brachytherapy with endoscopic ultrasound

Joseph Romagnuolo,Josée Parent,Té Vuong,Mélanie Bélanger,René P Michel,Paul J Belliveau,Judith L Trudel

DOI: https://doi.org/10.1155/2004/715393

Abstract:Background and study aims: A novel brachytherapy (BT) protocol evaluated at McGill University has shown promise in terms of downstaging and achieving high tumour sterilization rates in rectal cancer. Endoscopic ultrasound (EUS) has emerged as the imaging modality of choice for local staging of rectal cancer. However, external beam radiotherapy appears to decrease the accuracy of EUS from 85% to 40%. The aim of the present study was to prospectively evaluate the accuracy of EUS in assessing the response of rectal cancer to BT. Patients and methods: Thirty-three patients with locally advanced (stage T2 or T3) operable rectal carcinomas were included in an experimental protocol involving a novel conformal technique, using three-dimensional planning, to administer high-dose rate preoperative BT. The 18 patients who were able to have a post-BT EUS exam arranged within two weeks before surgery (eg, four to eight weeks post-BT) were included in this study. Tumour (T)- and lymph node (N)-staging on radial EUS, as well as interpretation of the residual tumour, were assessed prospectively. Pathologists were blinded to the post-BT EUS results. Results: The mean age was 70 years (SD +/- 11; range, 52 to 93 years) and 78% of the patients were male. Pre-BT EUS indicated that 16 patients (89%) were stage T3, and two were stage T2. Five patients (28%) had positive nodes (N1) by ultrasound. With BT, the mean maximal wall thickness on EUS decreased from 14 mm to 9.4 mm (P<0.001). At the time of surgery, seven of the 18 patients (39%) had no detectable tumour in the resected specimen; one had carcinoma in situ, one was stage T1, one was stage T2, and eight were stage T3. Eleven patients (61%) underwent an abdominoperineal resection, including four of the 11 (36%) with no ultimate evidence of residual carcinoma. Eight patients (44%) were node-positive. The sensitivity, specificity, and positive and negative predictive values of post-BT EUS in predicting residual tumour were 82%, 29%, 64% and 50%, respectively. The post-BT EUS accurately predicted the T-stage in eight (44%) patients; most errors were due to overstaging. Conclusions: Rectal cancer T-staging by EUS post-BT is inaccurate, and although it appears sensitive in predicting the presence or absence of residual tumor in rectal adenocarcinoma after preoperative BT, the low predictive values in this setting limit its utility at this time.
Comparative efficacy of Bacillus Calmette–Guérin instillation and radical cystectomy treatments for high-risk non-muscle-invasive urothelial cancer classified as high-grade T1 in initial and repeat transurethral resection of bladder tumor

Song Zhen,Chen Hao,Yu Yanhang,Lin Yuxin,Ouyang Jun,Zhang Zhiyu

DOI: https://doi.org/10.3389/fonc.2024.1394451

IF: 4.7

2024-06-19

Frontiers in Oncology

Abstract:Objective: To compare the differential therapeutic effects of Bacillus Calmette-Guérin (BCG) instillation and radical cystectomy (RC) for high-risk non-muscle–invasive urothelial cancer (NMIBC) classified as high-grade T1 in initial and repeat transurethral resection of bladder tumors (TURBT) and to construct a prediction model. Methods: We retrospectively analyzed the clinical data of patients with malignant bladder tumors treated at the First Affiliated Hospital of Soochow University from January 2016 to December 2017 and compared the differences in 1-year, 2-year, 3-year, 5-year, and comprehensive overall survival (OS) and progression-free survival (PFS) between BCG instillation treatment and RC treatment. Survival curves were drawn to show differences in OS and PFS between the two groups. Concurrently, univariate and multivariate COX analyses were performed to identify risk factors affecting OS and PFS, and a nomogram was created. Results: In total, 146 patients were included in the study, of whom 97 and 49 were in the BCG and RC groups, respectively. No statistical differences were observed in the 1- and 2-year OS and PFS between the two groups, whereas significant statistical differences were found in the 3-year, 5-year, and comprehensive OS and PFS. Survival curves also confirmed the statistical differences in OS and PFS between the BCG and RC groups. Multivariate COX analysis revealed that the treatment method, concomitant satellite lesions, and albumin-to-alkaline phosphatase ratio (AAPR) were independent risk factors affecting OS and PFS. The nomogram that was further plotted showed good predictive ability for OS and PFS. Conclusion: For patients who exhibit high-level T1 pathology after both initial and repeat TURBT, especially those with low AAPR, and concomitant satellite lesions, choosing RC as a treatment method offers a better prognosis.

oncology
[The possibilities for surgical correction of dentoalveolar adaptations within skeletal repositioning osteotomy].

P. Brachvogel,J. Berten,K. Hessling,J. Tränkmann

Fortschritte der Kieferorthopädie

Abstract:In the combined surgical orthodontic treatment the essential task is to eliminate the dentoalveolar adaptations of maxillofacial disorders. Additional segmental osteotomies can be considered if these adaptations are excessive or if complications are to be expected during the orthodontic treatment. Possibilities and indications as well as complications and limits of this approach are described.
Long-term oncologic outcomes and complications of robot-assisted radical cystectomy for the treatment of urothelial carcinoma of the bladder

Daniel J. Lama,Oluwatimilehin Okunowo,Jonathan Yamzon,Ali-Asghar Zhumkhawala,Timothy G. Wilson,Clayton S. Lau,Bertram E. Yuh,Kevin G. Chan

DOI: https://doi.org/10.1016/j.urolonc.2024.10.009

IF: 2.954

2024-10-24

Urologic Oncology Seminars and Original Investigations

Abstract:Introduction To report the long-term outcomes of robot-assisted radical cystectomy (RARC) for the treatment of muscle invasive and high-risk non-muscle invasive bladder cancer. Methods We reviewed a single tertiary center database of RARC from 2004 to 2020. Concomitant extended pelvic lymph node dissection and extracorporeal urinary diversion were performed. Cox regression analysis and the Kaplan-Meier method were used to identify factors associated with and report time-to-event estimations of recurrence-free survival and overall survival. Clavien-Dindo complications were identified, categorized, and substratified by time from surgery within 90-days and between 90-days and >5-years postoperatively. Results A total of 510 patients with median follow-up of 57.1 months (IQR 21.8–103.6) were included. Continent diversion was performed in 259 (51%) patients. Of the 340 (67%) ≥cT2 patients, 153 (45%) received cisplatin-based neoadjuvant chemotherapy. Recurrence was identified in 157 (31%) patients, and 118 (23%) died from bladder cancer. The overall complication rate was 52% with 267 (41%) major grade ≥ III events. Infectious (25%) and genitourinary (22%) complications were the most common irrespective of the time interval beyond 90-days. The risk of recurrence or death were increased by extravesical disease (HR 1.91 and 1.97, respectively) and lymph node positivity (HR 4.58 and 2.42, respectively) in multivariable analysis (all, P < 0.001). The estimated 5-, and 10-year recurrence-free and overall survival rates were 69% and 64% and 61% and 44%, respectively. Conclusions RARC is a durable treatment that optimizes the probability of cure for patients requiring extirpation for bladder cancer. Targeting the modifiable complications of radical surgery may further improve the risk/benefit ratio of RARC.

oncology,urology & nephrology

Synthesis and potent antiprotozoal activity of mono/di amidino 2-anilinobenzimidazoles versus Plasmodium falciparum and Trypanosoma brucei rhodesiense.

Transurethral En Bloc Resection Versus Standard Resection of Bladder Tumour: A Randomised, Multicentre, Phase 3 Trial

An international multicentre randomised controlled trial of en bloc resection of bladder tumour vs conventional transurethral resection of bladder tumour: first results of the en bloc resection of urothelium carcinoma of the bladder (EBRUC) II trial

Nonprescription Ibuprofen: Side Effect Profile

Efficiency of transurethral en‐bloc resection vs. conventional transurethral resection for non‐muscle‐invasive bladder cancer: An umbrella review

Sollten wir alle zur En Bloc Resektion von Blasentumoren wechseln?

Comparison of the efficacy and feasibility of en bloc transurethral resection of bladder tumor versus conventional transurethral resection of bladder tumor: A meta-analysis.

Using of en-bloc resection of the bladder wall with a tumor in the treatment of non-muscle invasive bladder cancer.

Minilaparoscopy-Assisted En Bloc Transurethral Resection Of Bladder Tumors

ERAS for Ambulatory TURBT: Enhancing Bladder Cancer Care (EMBRACE) randomised controlled trial protocol

Prognostic value of micrometric substaging in pT1 bladder cancer patients treated with en‐bloc transurethral resection

Thulium laser en bloc resection reduces recurrence rates in NMIBC patients with tumor diameters ≥3cm compared to transurethral resection: a non-randomized controlled study

On the Terminology of VVT

Organ-Sparing Strategies in Muscle-Invasive Bladder Cancer

High-power green-light laser endoscopic submucosal dissection for non-muscle-invasive bladder cancer: A technical improvement and its initial application

Transurethral plasma kinetic resection of superficial bladder tumor

Reducing recurrence in non-muscle-invasive bladder cancer by systematically implementing guideline-based recommendations: effect of a prospective intervention in primary bladder cancer patients

Predicting residual rectal adenocarcinoma in the surgical specimen after preoperative brachytherapy with endoscopic ultrasound

Comparative efficacy of Bacillus Calmette–Guérin instillation and radical cystectomy treatments for high-risk non-muscle-invasive urothelial cancer classified as high-grade T1 in initial and repeat transurethral resection of bladder tumor

[The possibilities for surgical correction of dentoalveolar adaptations within skeletal repositioning osteotomy].

Long-term oncologic outcomes and complications of robot-assisted radical cystectomy for the treatment of urothelial carcinoma of the bladder